NewAmsterdam Pharma Company NV
NAMS
查看详细走势图
35.110USD
+1.210+3.57%
收盘 12/19, 16:00（美东）报价延迟15分钟
3.97B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.57%
5天
-5.74%
1月
-8.26%
6月
+95.49%
今年开始到现在
+36.61%
1年
+37.69%
查看详细走势图
TradingKey NewAmsterdam Pharma Company NV股票评分
单位: USD 更新时间: 2025-12-19操作建议
NewAmsterdam Pharma Company NV当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名55/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价47.15。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
NewAmsterdam Pharma Company NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
15
位分析师
买入
评级
47.154
目标均价
+31.90%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
NewAmsterdam Pharma Company NV亮点
亮点风险
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
业绩增长期
公司处于发展阶段，最新年度总收入45.56M美元
利润高增长
公司净利润处于行业前列，最新年度总收入45.56M美元
估值低估
公司最新PE估值-17.20，处于3年历史低位
机构加仓
最新机构持股121.74M股，环比增加3.27%
ETHSX持仓
明星投资者ETHSX持仓，最新持仓市值479.00
NewAmsterdam Pharma Company NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
NewAmsterdam Pharma Company NV简介
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
公司代码NAMS
公司NewAmsterdam Pharma Company NV
CEODavidson (Michael Harvey)
网址https://ir.newamsterdampharma.com/
常见问题
NewAmsterdam Pharma Company NV(NAMS)的当前股价是多少？
NewAmsterdam Pharma Company NV(NAMS)的当前股价是 35.110。
NewAmsterdam Pharma Company NV的股票代码是什么？
NewAmsterdam Pharma Company NV的股票代码是NAMS。
NewAmsterdam Pharma Company NV股票的52周最高点是多少？
NewAmsterdam Pharma Company NV股票的52周最高点是42.000。
NewAmsterdam Pharma Company NV股票的52周最低点是多少？
NewAmsterdam Pharma Company NV股票的52周最低点是14.060。
NewAmsterdam Pharma Company NV的市值是多少？
NewAmsterdam Pharma Company NV的市值是3.97B。
NewAmsterdam Pharma Company NV的净利润是多少？
NewAmsterdam Pharma Company NV的净利润为-241.60M。
现在NewAmsterdam Pharma Company NV(NAMS)的股票是买入、持有还是卖出？
根据分析师评级，NewAmsterdam Pharma Company NV(NAMS)的总体评级为买入，目标价格为47.154。
NewAmsterdam Pharma Company NV(NAMS)股票的每股收益（EPS TTM）是多少
NewAmsterdam Pharma Company NV(NAMS)股票的每股收益（EPS TTM）是-2.041。
相关品种
